M
3MT
vs
D
DAX Index
Over the past 12 months, 3MT has underperformed DAX Index, delivering a return of 0% compared to the DAX Index's +13% growth.
Stocks Performance
3MT vs DAX Index
Performance Gap
3MT vs DAX Index
Performance By Year
3MT vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Magenta Therapeutics Inc
Glance View
Magenta Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. The company is headquartered in Cambridge, Massachusetts and currently employs 75 full-time employees. The company went IPO on 2018-06-21. The firm is developing medicines designed to bring the curative power of stem cell transplants to more patients with blood cancers, genetic diseases and autoimmune diseases. Its drug development pipeline includes multiple product candidates designed to improve stem cell transplants. Its lead clinical program is designed to mobilize and collect sufficient functional stem cells for use in stem cell transplantation, a process known as mobilization. The company is also developing product candidates that are designed to deplete targeted cells in the bone marrow to make space for the bone marrow to receive newly transplanted stem cells, a process known as conditioning. The firm's pipeline of stem cell transplant product candidates consists of MGTA-145, MGTA-117, C300, C100, G100, MGTA-456 and E478. The company is developing product candidates to be used individually or, in some cases, in combination with each other.
